Abstract
To examine long-term efficacy/safety of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, added to ongoing insulin therapy in Japanese patients with type 2 diabetes. We conducted a 36-week, open-label extension of ipragliflozin therapy following a 16-week, randomized, placebo-controlled, double-blind period (treatment periods II and I, respectively). Prior to the open-label period, patients taking insulin with/without a dipeptidyl peptidase-4 (DPP-4) inhibitor were randomized to receive placebo or 50 mg once-daily ipragliflozin. Oral antidiabetic drugs other than DPP-4 inhibitors were discontinued 4 weeks before screening. Following treatment period I, all patients received open-label ipragliflozin 50 mg, with the possibility of a dose increase to 100 mg at week 24 if HbA1c was ≥ 7.0% at week 20. Efficacy endpoints were changes in HbA1c, fasting plasma glucose (FPG), self-monitored blood glucose, bodyweight, and metabolic hormones. Drug-related treatment-emergent adverse events (TEAEs) were monitored for safety. Of 175 patients randomized to ipragliflozin, 168 entered treatment period II, 121 (69%) of whom completed this period. The mean ± standard deviation changes in HbA1c, FPG, and bodyweight from baseline (start of...Continue Reading
References
Jan 16, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T Yamauchi, T Kadowaki
Sep 29, 2011·Current Medical Research and Opinion·Stuart A RossJohn Ashkenas
Aug 6, 2013·Diabetes, Obesity & Metabolism·J P H WildingUNKNOWN Dapagliflozin 006 Study Group
Jun 13, 2014·Diabetes, Obesity & Metabolism·A KashiwagiA Utsuno
Oct 29, 2014·Diabetes, Obesity & Metabolism·A KashiwagiE Ueyama
Nov 21, 2014·Journal of Diabetes Investigation·Atsunori KashiwagiItsuro Nagase
Dec 30, 2014·Journal of Diabetes and Its Complications·Dragana Lovre, Vivian Fonseca
Mar 26, 2015·Acta Diabetologica·Matteo MonamiEdoardo Mannucci
Jun 5, 2015·Diabetes, Obesity & Metabolism·J RosenstockUNKNOWN EMPA-REG BASALTM trial investigators
Jun 25, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ted WuGreg Fulcher
Sep 15, 2015·Journal of Diabetes and Its Complications·Xiang-Yang LiuPei Yu
Oct 29, 2015·Diabetes/metabolism Research and Reviews·Jeremy PettusSteven Edelman
May 18, 2016·Journal of Diabetes Investigation·Eiichi ArakiToshitaka Yajima
Jun 19, 2016·Cardiovascular Diabetology·Nobuya InagakiHiroaki Iijima
Jul 21, 2016·Diabetes, Obesity & Metabolism·Hisamitsu IshiharaSeitaro Asahina
Oct 16, 2016·Journal of Clinical Medicine Research·Katsunori SuzukiMariko Hatta
Dec 18, 2016·Diabetes, Obesity & Metabolism·Eiichi ArakiToshitaka Yajima
Citations
Sep 26, 2019·Clinical Drug Investigation·Hisamitsu IshiharaYoshinori Kosakai
Aug 16, 2019·Postgraduate Medicine·Weiping ChenMulan Chen
Mar 22, 2019·Case Reports in Endocrinology·Miyako KishimotoMasayuki Adachi
Nov 29, 2020·BMJ Open Diabetes Research & Care·Takeshi HoriiKoichiro Atsuda